Published on 29/11/2025

Specification Setting for Potency/Identity: Guardbands

The correct specification setting for potency and identity is critical in the development and validation of biologics, including Advanced Therapy Medicinal Products (ATMPs). Utilizing guardbands provides a systematic approach to ensure product quality that aligns with regulatory standards set forth by the FDA, EMA, and other authorities. This tutorial will guide you through a step-by-step process, highlighting the importance of viral clearance validation, spiking studies, and considerations for closed and single-use systems in maintaining compliance.

Understanding Guardbands in Potency and Identity Specifications

Guardbands are essential components in the setting of specifications for potency and identity in biologic products. These optional ranges around a target value serve to create a buffer zone that accommodates variability in testing and manufacturing processes. Using guardbands addresses uncertainties that may impact the reliability of potency assays and identity validation, thereby aligning with regulatory expectations.

In practice, guardbands can be applied to various parameters involved in the characterization and validation of biologics. This includes potency assays that measure the biological activity or effectiveness of a therapeutic product. The concept was originally articulated in the ICH Q5A(R2), which outlines key considerations for assessing viral safety in biologics.

Planning for Potency and Identity Specifications

When planning your specifications for potency and identity, it is crucial to consider the following elements:

• Define the Target Products: Identify the specific characteristics for which the potency and identity will be assessed. This may include key quality attributes (CQAs) and their relationship to safety and efficacy.
• Identify Critical Quality Attributes (CQAs): These attributes can include potency identity, purity, and sterility. Understanding how they correlate with the desired therapeutic outcome is vital.
• Analyze Historical Data: Review past manufacturing and assay data to determine the variability in potency and identity measurements. This includes considering spiking studies results.

By harnessing this information, you can effectively outline the framework for your specifications, contributing to a robust Quality Management System (QMS).

Integrating Viral Clearance Validation

Viral clearance validation is an integral part of the overall strategy when setting specifications for potency and identity. It is essential to design a comprehensive plan that encompasses all potential viral contaminants throughout the production process. Key considerations include:

• Facility Design: Ensure that the production areas are designed in compliance with the latest aseptic controls as outlined in Annex 1.
• Selection of Viral Clearance Methods: Employ appropriate methods such as filtration, inactivation, or removal processes known to effectively eliminate viral contaminants.
• Conducting Spiking Studies: Design spiking studies that determine the efficacy of the chosen viral clearance methods. These should ensure enough data points to support your specifications.

Spiking Studies: A Critical Component

Spiking studies serve as experimental assays to assess the ability of your manufacturing process to eliminate viral contaminants effectively. These studies are vital to demonstrate the robustness and reliability of viral clearance in product pipelines:

• Study Design: Clearly define study parameters such as virus strains, concentration, and volume. Consider utilizing a range of viruses to represent potential contaminants adequately.
• Data Analysis: Analyze the outcome of your spiking studies by comparing the initial virus concentration to the final concentration detected post-manufacturing steps.
• Document Results: Maintain comprehensive records, including raw data, calculations, and conclusions. This documentation is essential for regulatory submissions and compliance.

Implementing Closed and Single-Use Systems

Utilizing closed and single-use systems reduces the risk of contamination and increases the reliability of product quality. However, to comply with regulatory expectations, certain considerations are necessary:

• System Selection: Choose systems that align with operational requirements while ensuring minimal risk of contamination and effective viral clearance capabilities.
• Training and Procedures: Ensure that personnel are trained in proper handling and use of these systems, including troubleshooting and maintenance guidelines.
• Validation of the System: Undertake thorough validation of the closed and single-use systems before utilizing them in production to establish their robustness.

Establishing a Chain of Identity Custody

Maintaining a precise chain of identity custody (COI) is paramount in the manufacture of biologics. This ensures traceability and minimizes the risk of cross-contamination or misidentification:

• Implement Tracking Systems: Utilize sophisticated tracking systems to monitor the product through every phase of production and testing. Each sample should have clear identification throughout.
• Redundancy in Tracking: Consider additional identification mechanisms, including RFID tagging or barcoding, to maintain enhanced traceability.
• Regular Audits: Conduct periodic audits to confirm adherence to the established COI protocols and address any discrepancies promptly.

PPQ and CPV Tailoring for ATMPs

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) cater to the specific needs of ATMP manufacturing. Tailoring these components for your products can enhance regulatory compliance:

• Developing PPQ Protocol: Plan and execute your PPQ according to the specific biological characteristics of your ATMP. This can include determining relevant CQAs, acceptance criteria, and testing frequency.
• Continuous Monitoring: Establish a CPV framework that systematically gathers and analyzes process data over time to ensure consistent production quality.
• Regulatory Insights: Stay informed about evolving regulatory guidelines from the FDA and EMA regarding PPQ and CPV to preemptively align your practices with best practices.

Conclusion

Setting specifications for potency and identity in biologics, specifically ATMPs, requires a meticulous approach that incorporates guardbands, viral clearance validation, spiking studies, and careful management of closed and single-use systems. By ensuring a robust framework around your process and adhering to regulatory guidance, the integrity of your biologic products can be maintained, aligning with both patient safety and regulatory expectations.

As pharmaceutical professionals, it is imperative to continuously adapt and evolve methodologies in response to regulatory developments, maintaining the highest standards of quality assurance and compliance.